AnteoTech Ltd. announced the appointment of Ms Katrina Byrne as Chief Operating Officer and the transition of Dr. Charlie Huang into the position of Chief Innovation Officer. In parallel, the Company will commence a recruitment process for a Chief Marketing Officer to further develop the marketing initiatives underway within the Company These changes reflect the Company's internal repositioning and align strategically with its transition from a pure research and development (R&D) company to a market-led sales driven business servicing customers across multiple sectors. As Chief Operating Officer, Ms Byrne will take a leadership role in building an organisational structure that facilitates the acceleration of project developments in AnteoTech's two core operating divisions - Life Sciences and Energy.

With advanced research operations across its project suite, AnteoTech has a unique opportunity to find commercial solutions through shared information and the broader knowledge base of its staff and leadership team. Ms Byrne's career experience in project management makes her the ideal candidate to help establish a nimble structure that will allow AnteoTech to move quickly with respect to the commercialisation of R&D breakthroughs. The transition of Dr. Huang to Chief Innovation Officer (CIO) is also targeted at the achievement of those same commercialisation objectives.

As Head of the Diagnostics and Life Science division since 2019, Huang has presided over the intellectual property portfolio and a multi-year clinical research operation for the group's EuGeni platform, which includes a novel detection technology for the COVID-19 virus and disease biomarkers. In his role as CIO, Huang will be responsible for the development of advanced technologies and innovative approaches to address market opportunities identified by the newly formed New Product Council primarily in the Life Sciences segment while also providing technical support to the Energy group to help accelerate commercialisation of the AnteoX and lithium-ion battery technology. Katrina Byrne joined AnteoTech as Head of Programs in July 2022 and will commence as Chief Operating Officer effective 31st October 2022.

Katrina has extensive domestic and international experience in operations, projects, and supply chain management across multiple industries including aerospace, defence, electronics manufacturing and resources, with a proven track record of growing and developing teams to facilitate the development and introduction of new products and capabilities. Her experience includes five years at Boeing introducing new products and capabilities in roles such as Operations Manager of the global Phantom Works division responsible for the rapid prototyping and development of advanced technologies. More recently Katrina worked with Airbus Australia Pacific (AAP) as Program Manager, Commercial Operations & Offers.

Katrina was a past Board Member of Women in Aviation International, Australian Chapter. She holds an MBA from the Australian Graduate School of Management and a Bachelor of Engineering - Manufacturing & Materials (Hons) from the University of Queensland. Dr. Charlie Huang joined AnteoTech in 2013 as Head of R&D and was appointed Head of Diagnostics and Life Science in 2019.

Charlie will commence as Chief Innovation Officer effective 31st October 2022. Prior to joining AnteoTech, he has held senior multi-discipline management roles in several listed healthcare and in vitro diagnostics companies including Panbio Ltd, Alere, Cellestis Ltd. and QIAGEN. He is working with the AnteoTech team to develop strategies, patents, products and services for industrial and life science applications and commercialisation.

He holds a BSc in Life Science and an MSc in Molecular Engineering from National Chung Hsing University, Taiwan. He obtained his PhD in Biochemistry and Molecular Biology from the University of Queensland.